UNSPSC 51263166: Metipranolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H27NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FBW237ALKD, chemically known as 4-(2-hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate but more generally known as metipranolol hydrochloride, which bears US NIH Compound Identifier 31477. European Medicines Agency schedules Metipranolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03267MIG.

UNSPSC 51263166 Metipranolol hydrochloride is a Commodity code nominally covering a specific beta-blocker pharmaceutical, but recent state and local solicitations tagged under this code show a significant mismatch with the actual work being procured. The two recent opportunities on record involve naloxone procurement and direct-to-manufacturer pharmacy programs — neither of which relates to metipranolol or ophthalmologic medications broadly. The code shows minimal relevant recent activity aligned with its pharmaceutical scope, and the opportunities present do not represent the kind of ongoing state and local demand patterns that would typically drive procurement under a specific active-pharmaceutical-ingredient classification.

Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, response due July 26, 2023; the Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription contracting models for a Therapeutic Pharmacy Initiative, with response due April 3, 2026. Both opportunities fall outside the metipranolol category. No other state or local solicitations under this code appear in the recent-opportunities block, and no pattern of repeat buyers or geographic concentration emerges. This code does not reflect active state and local procurement in its intended pharmaceutical domain at present.